Cann Group (CAN) AI Stock Analysis

• Market Cap: AU$7.98M
• Dividend Yield: N/A
• Average Volume (3M): 5.26M
• Price to Earnings (P/E): <0.1
• Beta (1Y): 0.64
• Revenue Growth: -26.49%
• EPS Growth: 61.72%
• Country: AU
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.03
• Shares Outstanding: 1,596,783,300
• 10 Day Avg. Volume: 7,033,578
• 30 Day Avg. Volume: 5,261,608
• PEG Ratio: <0.01
• Price to Book (P/B): -1.90
• Price to Sales (P/S): 0.40
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: AU$0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 01/10/26
• Date: Action: Reiterated 01/10/26

The score is primarily driven down by very weak financial performance (large losses, negative equity, and negative cash flows). Technicals add modest additional pressure due to a downtrend and negative MACD, while valuation is also constrained by a negative P/E and no dividend support.

Positive Factors

Integrated supply chain

Owning cultivation, manufacturing and distribution provides durable operational control over product quality, regulatory compliance and supply reliability. This vertical integration can sustain margins, shorten time-to-market for new products, and support scaling into new markets over months.

Negative Factors

Negative equity / solvency risk

Negative shareholders' equity and extreme leverage signal structural solvency risk and constrain access to inexpensive capital. Over a multi-month horizon this limits strategic flexibility, increases refinancing risk, and may force dilutive or costly funding solutions to sustain operations.

Cann Group Business Overview & Revenue Model

Company Description

Cann Group Limited engages in the breeding, cultivation, production, manufacturing, clinical evaluation, and supplying medicinal cannabis for sale and use within Australia and for overseas export markets. It licenses to undertake research and to c...

Read more

Cann Group Limited engages in the breeding, cultivation, production, manufacturing, clinical evaluation, and supplying medicinal cannabis for sale and use within Australia and for overseas export markets. It licenses to undertake research and to c...

How the Company Makes Money

Cann Group generates revenue through multiple key streams, primarily from the sale of medicinal cannabis products to patients and healthcare providers. The company has established a cultivation facility that allows it to produce high-quality canna...

Read more

Cann Group generates revenue through multiple key streams, primarily from the sale of medicinal cannabis products to patients and healthcare providers. The company has established a cultivation facility that allows it to produce high-quality canna...

Cann Group Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	11.31M	13.25M	15.37M	13.78M	6.41M	4.29M
Gross Profit	-2.35M	5.15M	-21.75M	20.63M	11.24M	4.25M
EBITDA	-7.37M	-8.94M	-35.54M	-24.63M	-24.36M	-22.55M
Net Income	14.73M	-22.34M	-51.24M	-33.79M	-26.47M	-25.10M
Balance Sheet
Total Assets	55.54M	78.79M	92.77M	129.47M	139.66M	101.79M
Cash, Cash Equivalents and Short-Term Investments	955.00K	10.00K	1.64M	765.00K	1.91M	3.10M
Total Debt	15.10M	75.84M	72.47M	60.97M	47.16M	680.00K
Total Liabilities	21.39M	81.56M	78.85M	70.20M	54.76M	9.92M
Stockholders Equity	34.16M	-2.77M	13.92M	59.26M	84.90M	91.87M
Cash Flow
Free Cash Flow	-5.31M	-9.80M	-17.69M	-25.94M	-65.60M	-37.10M
Operating Cash Flow	-5.12M	-9.64M	-15.19M	-22.84M	-20.43M	-20.83M
Investing Cash Flow	-193.00K	-157.00K	1.18M	-28.00K	-45.16M	-17.08M
Financing Cash Flow	6.21M	8.17M	14.77M	21.71M	64.41M	39.47M

Cann Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CAN, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.75 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CAN.

Cann Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	57 Neutral	AU$27.84M	-12.06	1.66%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXL	48 Neutral	AU$2.90M	-0.42	-76.30%	―	36.60%	85.28%
IDT	45 Neutral	AU$18.51M	-4.15	-29.05%	―	45.30%	-24.18%
PKP	43 Neutral	AU$18.57M	-2.87	4388.00%	―	-47.30%	82.53%
CAN	39 Underperform	AU$7.98M	0.07	93.89%	―	-26.49%	61.72%

Cann Group Corporate Events